nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—Metoclopramide—DRD3—attention deficit hyperactivity disorder	0.00659	0.591	CrCbGaD
Sunitinib—Metoclopramide—DRD2—attention deficit hyperactivity disorder	0.00456	0.409	CrCbGaD
Sunitinib—AURKC—brain—attention deficit hyperactivity disorder	0.000849	0.00149	CbGeAlD
Sunitinib—ROCK1—central nervous system—attention deficit hyperactivity disorder	0.000847	0.00149	CbGeAlD
Sunitinib—STK10—cardiovascular system—attention deficit hyperactivity disorder	0.000844	0.00148	CbGeAlD
Sunitinib—CSNK1G2—brain—attention deficit hyperactivity disorder	0.000842	0.00148	CbGeAlD
Sunitinib—PKN1—brain—attention deficit hyperactivity disorder	0.000842	0.00148	CbGeAlD
Sunitinib—TAOK3—cardiovascular system—attention deficit hyperactivity disorder	0.000841	0.00148	CbGeAlD
Sunitinib—STK3—cerebellum—attention deficit hyperactivity disorder	0.000839	0.00147	CbGeAlD
Sunitinib—MERTK—nervous system—attention deficit hyperactivity disorder	0.000838	0.00147	CbGeAlD
Sunitinib—MAP3K7—midbrain—attention deficit hyperactivity disorder	0.000837	0.00147	CbGeAlD
Sunitinib—PDGFRA—cardiovascular system—attention deficit hyperactivity disorder	0.000836	0.00147	CbGeAlD
Sunitinib—PRPF4—brain—attention deficit hyperactivity disorder	0.00083	0.00146	CbGeAlD
Sunitinib—TBK1—midbrain—attention deficit hyperactivity disorder	0.000827	0.00145	CbGeAlD
Sunitinib—DYRK1A—central nervous system—attention deficit hyperactivity disorder	0.000826	0.00145	CbGeAlD
Sunitinib—MAP4K4—nervous system—attention deficit hyperactivity disorder	0.000823	0.00144	CbGeAlD
Sunitinib—TYK2—midbrain—attention deficit hyperactivity disorder	0.000822	0.00144	CbGeAlD
Sunitinib—PRPF4B—brain—attention deficit hyperactivity disorder	0.000818	0.00144	CbGeAlD
Sunitinib—IRAK1—midbrain—attention deficit hyperactivity disorder	0.000811	0.00142	CbGeAlD
Sunitinib—MAP3K12—nervous system—attention deficit hyperactivity disorder	0.000811	0.00142	CbGeAlD
Sunitinib—DYRK1A—cerebellum—attention deficit hyperactivity disorder	0.000807	0.00142	CbGeAlD
Sunitinib—MERTK—central nervous system—attention deficit hyperactivity disorder	0.000807	0.00142	CbGeAlD
Sunitinib—STK39—brain—attention deficit hyperactivity disorder	0.000807	0.00142	CbGeAlD
Sunitinib—RPS6KA3—nervous system—attention deficit hyperactivity disorder	0.0008	0.0014	CbGeAlD
Sunitinib—CSNK2A1—brain—attention deficit hyperactivity disorder	0.000796	0.0014	CbGeAlD
Sunitinib—RPS6KB1—midbrain—attention deficit hyperactivity disorder	0.000796	0.0014	CbGeAlD
Sunitinib—MAP2K1—nervous system—attention deficit hyperactivity disorder	0.000795	0.00139	CbGeAlD
Sunitinib—MAP4K4—central nervous system—attention deficit hyperactivity disorder	0.000792	0.00139	CbGeAlD
Sunitinib—RET—midbrain—attention deficit hyperactivity disorder	0.000791	0.00139	CbGeAlD
Sunitinib—MERTK—cerebellum—attention deficit hyperactivity disorder	0.000789	0.00138	CbGeAlD
Sunitinib—AXL—midbrain—attention deficit hyperactivity disorder	0.000788	0.00138	CbGeAlD
Sunitinib—MYLK—brain—attention deficit hyperactivity disorder	0.000786	0.00138	CbGeAlD
Sunitinib—CSNK1A1—nervous system—attention deficit hyperactivity disorder	0.000784	0.00138	CbGeAlD
Sunitinib—MAP3K12—central nervous system—attention deficit hyperactivity disorder	0.000781	0.00137	CbGeAlD
Sunitinib—CLK1—nervous system—attention deficit hyperactivity disorder	0.000779	0.00137	CbGeAlD
Sunitinib—PLK4—brain—attention deficit hyperactivity disorder	0.000776	0.00136	CbGeAlD
Sunitinib—MAP4K4—cerebellum—attention deficit hyperactivity disorder	0.000774	0.00136	CbGeAlD
Sunitinib—STK4—brain—attention deficit hyperactivity disorder	0.000771	0.00135	CbGeAlD
Sunitinib—RPS6KA3—central nervous system—attention deficit hyperactivity disorder	0.00077	0.00135	CbGeAlD
Sunitinib—NUAK2—cerebellum—attention deficit hyperactivity disorder	0.000769	0.00135	CbGeAlD
Sunitinib—MAP2K1—central nervous system—attention deficit hyperactivity disorder	0.000765	0.00134	CbGeAlD
Sunitinib—CAMK2G—nervous system—attention deficit hyperactivity disorder	0.000765	0.00134	CbGeAlD
Sunitinib—BMP2K—nervous system—attention deficit hyperactivity disorder	0.000765	0.00134	CbGeAlD
Sunitinib—MAP3K12—cerebellum—attention deficit hyperactivity disorder	0.000763	0.00134	CbGeAlD
Sunitinib—FLT3—cerebellum—attention deficit hyperactivity disorder	0.000763	0.00134	CbGeAlD
Sunitinib—SLK—midbrain—attention deficit hyperactivity disorder	0.000758	0.00133	CbGeAlD
Sunitinib—LRRK2—nervous system—attention deficit hyperactivity disorder	0.000758	0.00133	CbGeAlD
Sunitinib—PHKG2—brain—attention deficit hyperactivity disorder	0.000758	0.00133	CbGeAlD
Sunitinib—CSNK1A1—central nervous system—attention deficit hyperactivity disorder	0.000755	0.00133	CbGeAlD
Sunitinib—MAP2K5—cardiovascular system—attention deficit hyperactivity disorder	0.000754	0.00132	CbGeAlD
Sunitinib—KDR—cardiovascular system—attention deficit hyperactivity disorder	0.000754	0.00132	CbGeAlD
Sunitinib—STK24—brain—attention deficit hyperactivity disorder	0.000753	0.00132	CbGeAlD
Sunitinib—RPS6KA3—cerebellum—attention deficit hyperactivity disorder	0.000753	0.00132	CbGeAlD
Sunitinib—CLK1—central nervous system—attention deficit hyperactivity disorder	0.00075	0.00132	CbGeAlD
Sunitinib—MAP2K1—cerebellum—attention deficit hyperactivity disorder	0.000748	0.00131	CbGeAlD
Sunitinib—PRKAA1—nervous system—attention deficit hyperactivity disorder	0.000747	0.00131	CbGeAlD
Sunitinib—DAPK2—brain—attention deficit hyperactivity disorder	0.000745	0.00131	CbGeAlD
Sunitinib—PTK2B—nervous system—attention deficit hyperactivity disorder	0.000739	0.0013	CbGeAlD
Sunitinib—CSNK1A1—cerebellum—attention deficit hyperactivity disorder	0.000738	0.0013	CbGeAlD
Sunitinib—FYN—midbrain—attention deficit hyperactivity disorder	0.000737	0.00129	CbGeAlD
Sunitinib—CAMK2G—central nervous system—attention deficit hyperactivity disorder	0.000736	0.00129	CbGeAlD
Sunitinib—BMP2K—central nervous system—attention deficit hyperactivity disorder	0.000736	0.00129	CbGeAlD
Sunitinib—CSF1R—cardiovascular system—attention deficit hyperactivity disorder	0.000736	0.00129	CbGeAlD
Sunitinib—CLK1—cerebellum—attention deficit hyperactivity disorder	0.000733	0.00129	CbGeAlD
Sunitinib—STK16—brain—attention deficit hyperactivity disorder	0.000733	0.00129	CbGeAlD
Sunitinib—LRRK2—central nervous system—attention deficit hyperactivity disorder	0.00073	0.00128	CbGeAlD
Sunitinib—HIPK2—brain—attention deficit hyperactivity disorder	0.000729	0.00128	CbGeAlD
Sunitinib—HIPK3—brain—attention deficit hyperactivity disorder	0.000729	0.00128	CbGeAlD
Sunitinib—ALK—brain—attention deficit hyperactivity disorder	0.000729	0.00128	CbGeAlD
Sunitinib—TYRO3—brain—attention deficit hyperactivity disorder	0.000729	0.00128	CbGeAlD
Sunitinib—CSNK1E—nervous system—attention deficit hyperactivity disorder	0.000727	0.00128	CbGeAlD
Sunitinib—TNK1—brain—attention deficit hyperactivity disorder	0.000722	0.00127	CbGeAlD
Sunitinib—RIOK2—brain—attention deficit hyperactivity disorder	0.000722	0.00127	CbGeAlD
Sunitinib—MAP4K5—midbrain—attention deficit hyperactivity disorder	0.000721	0.00127	CbGeAlD
Sunitinib—MAP3K3—midbrain—attention deficit hyperactivity disorder	0.000721	0.00127	CbGeAlD
Sunitinib—CAMK2G—cerebellum—attention deficit hyperactivity disorder	0.00072	0.00126	CbGeAlD
Sunitinib—BMP2K—cerebellum—attention deficit hyperactivity disorder	0.00072	0.00126	CbGeAlD
Sunitinib—PRKAA1—central nervous system—attention deficit hyperactivity disorder	0.000719	0.00126	CbGeAlD
Sunitinib—IRAK4—nervous system—attention deficit hyperactivity disorder	0.000715	0.00126	CbGeAlD
Sunitinib—MAP3K19—brain—attention deficit hyperactivity disorder	0.000714	0.00125	CbGeAlD
Sunitinib—MAP4K1—brain—attention deficit hyperactivity disorder	0.000714	0.00125	CbGeAlD
Sunitinib—LRRK2—cerebellum—attention deficit hyperactivity disorder	0.000713	0.00125	CbGeAlD
Sunitinib—PTK2B—central nervous system—attention deficit hyperactivity disorder	0.000711	0.00125	CbGeAlD
Sunitinib—PRKAA1—cerebellum—attention deficit hyperactivity disorder	0.000703	0.00123	CbGeAlD
Sunitinib—DAPK3—brain—attention deficit hyperactivity disorder	0.0007	0.00123	CbGeAlD
Sunitinib—CSNK1E—central nervous system—attention deficit hyperactivity disorder	0.0007	0.00123	CbGeAlD
Sunitinib—MAP2K2—nervous system—attention deficit hyperactivity disorder	0.0007	0.00123	CbGeAlD
Sunitinib—ULK3—nervous system—attention deficit hyperactivity disorder	0.0007	0.00123	CbGeAlD
Sunitinib—FLT1—midbrain—attention deficit hyperactivity disorder	0.000697	0.00122	CbGeAlD
Sunitinib—PTK2B—cerebellum—attention deficit hyperactivity disorder	0.000695	0.00122	CbGeAlD
Sunitinib—MAP3K2—nervous system—attention deficit hyperactivity disorder	0.000694	0.00122	CbGeAlD
Sunitinib—CLK2—brain—attention deficit hyperactivity disorder	0.000694	0.00122	CbGeAlD
Sunitinib—MAP4K2—brain—attention deficit hyperactivity disorder	0.000691	0.00121	CbGeAlD
Sunitinib—IRAK4—central nervous system—attention deficit hyperactivity disorder	0.000689	0.00121	CbGeAlD
Sunitinib—EPHB6—midbrain—attention deficit hyperactivity disorder	0.000689	0.00121	CbGeAlD
Sunitinib—CSNK1E—cerebellum—attention deficit hyperactivity disorder	0.000684	0.0012	CbGeAlD
Sunitinib—FGFR1—cerebellum—attention deficit hyperactivity disorder	0.000684	0.0012	CbGeAlD
Sunitinib—STK3—brain—attention deficit hyperactivity disorder	0.000681	0.0012	CbGeAlD
Sunitinib—TBK1—nervous system—attention deficit hyperactivity disorder	0.00068	0.00119	CbGeAlD
Sunitinib—TYK2—nervous system—attention deficit hyperactivity disorder	0.000676	0.00119	CbGeAlD
Sunitinib—MAP2K2—central nervous system—attention deficit hyperactivity disorder	0.000673	0.00118	CbGeAlD
Sunitinib—ULK3—central nervous system—attention deficit hyperactivity disorder	0.000673	0.00118	CbGeAlD
Sunitinib—IRAK4—cerebellum—attention deficit hyperactivity disorder	0.000673	0.00118	CbGeAlD
Sunitinib—ROCK1—brain—attention deficit hyperactivity disorder	0.000672	0.00118	CbGeAlD
Sunitinib—MAP3K2—central nervous system—attention deficit hyperactivity disorder	0.000669	0.00117	CbGeAlD
Sunitinib—KIT—cardiovascular system—attention deficit hyperactivity disorder	0.000668	0.00117	CbGeAlD
Sunitinib—YES1—midbrain—attention deficit hyperactivity disorder	0.000666	0.00117	CbGeAlD
Sunitinib—MAP2K2—cerebellum—attention deficit hyperactivity disorder	0.000658	0.00116	CbGeAlD
Sunitinib—ULK3—cerebellum—attention deficit hyperactivity disorder	0.000658	0.00116	CbGeAlD
Sunitinib—TAOK3—midbrain—attention deficit hyperactivity disorder	0.000657	0.00115	CbGeAlD
Sunitinib—DYRK1A—brain—attention deficit hyperactivity disorder	0.000656	0.00115	CbGeAlD
Sunitinib—TBK1—central nervous system—attention deficit hyperactivity disorder	0.000655	0.00115	CbGeAlD
Sunitinib—RPS6KB1—nervous system—attention deficit hyperactivity disorder	0.000654	0.00115	CbGeAlD
Sunitinib—MAP3K2—cerebellum—attention deficit hyperactivity disorder	0.000654	0.00115	CbGeAlD
Sunitinib—PDGFRB—cardiovascular system—attention deficit hyperactivity disorder	0.000653	0.00115	CbGeAlD
Sunitinib—TYK2—central nervous system—attention deficit hyperactivity disorder	0.00065	0.00114	CbGeAlD
Sunitinib—FGR—nervous system—attention deficit hyperactivity disorder	0.00065	0.00114	CbGeAlD
Sunitinib—RET—nervous system—attention deficit hyperactivity disorder	0.00065	0.00114	CbGeAlD
Sunitinib—AXL—nervous system—attention deficit hyperactivity disorder	0.000648	0.00114	CbGeAlD
Sunitinib—MAP3K7—cerebellum—attention deficit hyperactivity disorder	0.000647	0.00114	CbGeAlD
Sunitinib—MERTK—brain—attention deficit hyperactivity disorder	0.000641	0.00112	CbGeAlD
Sunitinib—TBK1—cerebellum—attention deficit hyperactivity disorder	0.00064	0.00112	CbGeAlD
Sunitinib—TYK2—cerebellum—attention deficit hyperactivity disorder	0.000636	0.00112	CbGeAlD
Sunitinib—RPS6KB1—central nervous system—attention deficit hyperactivity disorder	0.00063	0.00111	CbGeAlD
Sunitinib—MAP4K4—brain—attention deficit hyperactivity disorder	0.000629	0.0011	CbGeAlD
Sunitinib—IRAK1—cerebellum—attention deficit hyperactivity disorder	0.000627	0.0011	CbGeAlD
Sunitinib—FGR—central nervous system—attention deficit hyperactivity disorder	0.000626	0.0011	CbGeAlD
Sunitinib—RET—central nervous system—attention deficit hyperactivity disorder	0.000626	0.0011	CbGeAlD
Sunitinib—NUAK2—brain—attention deficit hyperactivity disorder	0.000624	0.0011	CbGeAlD
Sunitinib—AXL—central nervous system—attention deficit hyperactivity disorder	0.000624	0.00109	CbGeAlD
Sunitinib—MAP3K12—brain—attention deficit hyperactivity disorder	0.00062	0.00109	CbGeAlD
Sunitinib—FGFR2—nervous system—attention deficit hyperactivity disorder	0.000618	0.00108	CbGeAlD
Sunitinib—RPS6KB1—cerebellum—attention deficit hyperactivity disorder	0.000616	0.00108	CbGeAlD
Sunitinib—ABCC4—forebrain—attention deficit hyperactivity disorder	0.000615	0.00108	CbGeAlD
Sunitinib—JAK2—nervous system—attention deficit hyperactivity disorder	0.000615	0.00108	CbGeAlD
Sunitinib—RET—cerebellum—attention deficit hyperactivity disorder	0.000612	0.00107	CbGeAlD
Sunitinib—RPS6KA3—brain—attention deficit hyperactivity disorder	0.000611	0.00107	CbGeAlD
Sunitinib—AXL—cerebellum—attention deficit hyperactivity disorder	0.00061	0.00107	CbGeAlD
Sunitinib—MAP2K1—brain—attention deficit hyperactivity disorder	0.000607	0.00107	CbGeAlD
Sunitinib—FYN—nervous system—attention deficit hyperactivity disorder	0.000606	0.00106	CbGeAlD
Sunitinib—CSNK1A1—brain—attention deficit hyperactivity disorder	0.000599	0.00105	CbGeAlD
Sunitinib—CLK1—brain—attention deficit hyperactivity disorder	0.000596	0.00105	CbGeAlD
Sunitinib—FGFR2—central nervous system—attention deficit hyperactivity disorder	0.000595	0.00104	CbGeAlD
Sunitinib—MAP4K5—nervous system—attention deficit hyperactivity disorder	0.000592	0.00104	CbGeAlD
Sunitinib—MAP3K3—nervous system—attention deficit hyperactivity disorder	0.000592	0.00104	CbGeAlD
Sunitinib—JAK2—central nervous system—attention deficit hyperactivity disorder	0.000592	0.00104	CbGeAlD
Sunitinib—MAP2K5—midbrain—attention deficit hyperactivity disorder	0.000589	0.00103	CbGeAlD
Sunitinib—KDR—midbrain—attention deficit hyperactivity disorder	0.000589	0.00103	CbGeAlD
Sunitinib—SLK—cerebellum—attention deficit hyperactivity disorder	0.000587	0.00103	CbGeAlD
Sunitinib—CAMK2G—brain—attention deficit hyperactivity disorder	0.000585	0.00103	CbGeAlD
Sunitinib—BMP2K—brain—attention deficit hyperactivity disorder	0.000585	0.00103	CbGeAlD
Sunitinib—FYN—central nervous system—attention deficit hyperactivity disorder	0.000584	0.00102	CbGeAlD
Sunitinib—FGFR2—cerebellum—attention deficit hyperactivity disorder	0.000581	0.00102	CbGeAlD
Sunitinib—LRRK2—brain—attention deficit hyperactivity disorder	0.000579	0.00102	CbGeAlD
Sunitinib—JAK2—cerebellum—attention deficit hyperactivity disorder	0.000578	0.00102	CbGeAlD
Sunitinib—CSF1R—midbrain—attention deficit hyperactivity disorder	0.000575	0.00101	CbGeAlD
Sunitinib—FLT1—nervous system—attention deficit hyperactivity disorder	0.000573	0.00101	CbGeAlD
Sunitinib—PRKAA1—brain—attention deficit hyperactivity disorder	0.000571	0.001	CbGeAlD
Sunitinib—FYN—cerebellum—attention deficit hyperactivity disorder	0.00057	0.001	CbGeAlD
Sunitinib—MAP3K3—central nervous system—attention deficit hyperactivity disorder	0.00057	0.001	CbGeAlD
Sunitinib—MAP4K5—central nervous system—attention deficit hyperactivity disorder	0.00057	0.001	CbGeAlD
Sunitinib—EPHB6—nervous system—attention deficit hyperactivity disorder	0.000566	0.000994	CbGeAlD
Sunitinib—PTK2B—brain—attention deficit hyperactivity disorder	0.000565	0.000991	CbGeAlD
Sunitinib—FLT4—brain—attention deficit hyperactivity disorder	0.000563	0.000989	CbGeAlD
Sunitinib—MAP4K5—cerebellum—attention deficit hyperactivity disorder	0.000557	0.000979	CbGeAlD
Sunitinib—MAP3K3—cerebellum—attention deficit hyperactivity disorder	0.000557	0.000979	CbGeAlD
Sunitinib—FGFR1—brain—attention deficit hyperactivity disorder	0.000555	0.000975	CbGeAlD
Sunitinib—CSNK1E—brain—attention deficit hyperactivity disorder	0.000555	0.000975	CbGeAlD
Sunitinib—FLT1—central nervous system—attention deficit hyperactivity disorder	0.000551	0.000968	CbGeAlD
Sunitinib—YES1—nervous system—attention deficit hyperactivity disorder	0.000547	0.000961	CbGeAlD
Sunitinib—IRAK4—brain—attention deficit hyperactivity disorder	0.000547	0.00096	CbGeAlD
Sunitinib—EPHB6—central nervous system—attention deficit hyperactivity disorder	0.000545	0.000957	CbGeAlD
Sunitinib—STK10—nervous system—attention deficit hyperactivity disorder	0.000542	0.000952	CbGeAlD
Sunitinib—TAOK3—nervous system—attention deficit hyperactivity disorder	0.00054	0.000948	CbGeAlD
Sunitinib—FLT1—cerebellum—attention deficit hyperactivity disorder	0.000539	0.000946	CbGeAlD
Sunitinib—PDGFRA—nervous system—attention deficit hyperactivity disorder	0.000537	0.000942	CbGeAlD
Sunitinib—MAP2K2—brain—attention deficit hyperactivity disorder	0.000535	0.000939	CbGeAlD
Sunitinib—ULK3—brain—attention deficit hyperactivity disorder	0.000535	0.000939	CbGeAlD
Sunitinib—EPHB6—cerebellum—attention deficit hyperactivity disorder	0.000533	0.000935	CbGeAlD
Sunitinib—MAP3K2—brain—attention deficit hyperactivity disorder	0.000531	0.000932	CbGeAlD
Sunitinib—YES1—central nervous system—attention deficit hyperactivity disorder	0.000527	0.000925	CbGeAlD
Sunitinib—MAP3K7—brain—attention deficit hyperactivity disorder	0.000526	0.000923	CbGeAlD
Sunitinib—STK10—central nervous system—attention deficit hyperactivity disorder	0.000522	0.000916	CbGeAlD
Sunitinib—KIT—midbrain—attention deficit hyperactivity disorder	0.000522	0.000916	CbGeAlD
Sunitinib—TAOK3—central nervous system—attention deficit hyperactivity disorder	0.00052	0.000913	CbGeAlD
Sunitinib—TBK1—brain—attention deficit hyperactivity disorder	0.00052	0.000913	CbGeAlD
Sunitinib—PDGFRA—central nervous system—attention deficit hyperactivity disorder	0.000517	0.000907	CbGeAlD
Sunitinib—TYK2—brain—attention deficit hyperactivity disorder	0.000516	0.000907	CbGeAlD
Sunitinib—YES1—cerebellum—attention deficit hyperactivity disorder	0.000515	0.000904	CbGeAlD
Sunitinib—STK10—cerebellum—attention deficit hyperactivity disorder	0.00051	0.000896	CbGeAlD
Sunitinib—PDGFRB—midbrain—attention deficit hyperactivity disorder	0.00051	0.000895	CbGeAlD
Sunitinib—IRAK1—brain—attention deficit hyperactivity disorder	0.00051	0.000895	CbGeAlD
Sunitinib—TAOK3—cerebellum—attention deficit hyperactivity disorder	0.000508	0.000892	CbGeAlD
Sunitinib—PDGFRA—cerebellum—attention deficit hyperactivity disorder	0.000505	0.000887	CbGeAlD
Sunitinib—RPS6KB1—brain—attention deficit hyperactivity disorder	0.0005	0.000878	CbGeAlD
Sunitinib—FGR—brain—attention deficit hyperactivity disorder	0.000497	0.000873	CbGeAlD
Sunitinib—RET—brain—attention deficit hyperactivity disorder	0.000497	0.000873	CbGeAlD
Sunitinib—AXL—brain—attention deficit hyperactivity disorder	0.000495	0.000869	CbGeAlD
Sunitinib—KCNH2—forebrain—attention deficit hyperactivity disorder	0.000488	0.000856	CbGeAlD
Sunitinib—KDR—nervous system—attention deficit hyperactivity disorder	0.000484	0.00085	CbGeAlD
Sunitinib—MAP2K5—nervous system—attention deficit hyperactivity disorder	0.000484	0.00085	CbGeAlD
Sunitinib—SLK—brain—attention deficit hyperactivity disorder	0.000477	0.000837	CbGeAlD
Sunitinib—CSF1R—nervous system—attention deficit hyperactivity disorder	0.000473	0.00083	CbGeAlD
Sunitinib—FGFR2—brain—attention deficit hyperactivity disorder	0.000472	0.000829	CbGeAlD
Sunitinib—JAK2—brain—attention deficit hyperactivity disorder	0.00047	0.000825	CbGeAlD
Sunitinib—MAP2K5—central nervous system—attention deficit hyperactivity disorder	0.000466	0.000818	CbGeAlD
Sunitinib—KDR—central nervous system—attention deficit hyperactivity disorder	0.000466	0.000818	CbGeAlD
Sunitinib—FYN—brain—attention deficit hyperactivity disorder	0.000463	0.000814	CbGeAlD
Sunitinib—KDR—cerebellum—attention deficit hyperactivity disorder	0.000456	0.0008	CbGeAlD
Sunitinib—MAP2K5—cerebellum—attention deficit hyperactivity disorder	0.000456	0.0008	CbGeAlD
Sunitinib—CSF1R—central nervous system—attention deficit hyperactivity disorder	0.000455	0.000799	CbGeAlD
Sunitinib—MAP4K5—brain—attention deficit hyperactivity disorder	0.000453	0.000795	CbGeAlD
Sunitinib—MAP3K3—brain—attention deficit hyperactivity disorder	0.000453	0.000795	CbGeAlD
Sunitinib—CSF1R—cerebellum—attention deficit hyperactivity disorder	0.000445	0.000781	CbGeAlD
Sunitinib—FLT1—brain—attention deficit hyperactivity disorder	0.000438	0.000769	CbGeAlD
Sunitinib—EPHB6—brain—attention deficit hyperactivity disorder	0.000433	0.00076	CbGeAlD
Sunitinib—KIT—nervous system—attention deficit hyperactivity disorder	0.000429	0.000753	CbGeAlD
Sunitinib—PDGFRB—nervous system—attention deficit hyperactivity disorder	0.000419	0.000736	CbGeAlD
Sunitinib—YES1—brain—attention deficit hyperactivity disorder	0.000418	0.000734	CbGeAlD
Sunitinib—STK10—brain—attention deficit hyperactivity disorder	0.000414	0.000728	CbGeAlD
Sunitinib—KIT—central nervous system—attention deficit hyperactivity disorder	0.000413	0.000725	CbGeAlD
Sunitinib—TAOK3—brain—attention deficit hyperactivity disorder	0.000413	0.000725	CbGeAlD
Sunitinib—KCNH2—cardiovascular system—attention deficit hyperactivity disorder	0.000412	0.000724	CbGeAlD
Sunitinib—PDGFRA—brain—attention deficit hyperactivity disorder	0.00041	0.00072	CbGeAlD
Sunitinib—KIT—cerebellum—attention deficit hyperactivity disorder	0.000404	0.000709	CbGeAlD
Sunitinib—PDGFRB—central nervous system—attention deficit hyperactivity disorder	0.000403	0.000708	CbGeAlD
Sunitinib—PDGFRB—cerebellum—attention deficit hyperactivity disorder	0.000394	0.000692	CbGeAlD
Sunitinib—KDR—brain—attention deficit hyperactivity disorder	0.00037	0.00065	CbGeAlD
Sunitinib—MAP2K5—brain—attention deficit hyperactivity disorder	0.00037	0.00065	CbGeAlD
Sunitinib—CSF1R—brain—attention deficit hyperactivity disorder	0.000361	0.000634	CbGeAlD
Sunitinib—ABCC4—nervous system—attention deficit hyperactivity disorder	0.000334	0.000586	CbGeAlD
Sunitinib—KIT—brain—attention deficit hyperactivity disorder	0.000328	0.000576	CbGeAlD
Sunitinib—KCNH2—midbrain—attention deficit hyperactivity disorder	0.000322	0.000565	CbGeAlD
Sunitinib—ABCC4—central nervous system—attention deficit hyperactivity disorder	0.000321	0.000564	CbGeAlD
Sunitinib—PDGFRB—brain—attention deficit hyperactivity disorder	0.00032	0.000562	CbGeAlD
Sunitinib—ABCG2—midbrain—attention deficit hyperactivity disorder	0.000287	0.000503	CbGeAlD
Sunitinib—KCNH2—nervous system—attention deficit hyperactivity disorder	0.000265	0.000465	CbGeAlD
Sunitinib—ABCC4—brain—attention deficit hyperactivity disorder	0.000255	0.000448	CbGeAlD
Sunitinib—KCNH2—central nervous system—attention deficit hyperactivity disorder	0.000255	0.000448	CbGeAlD
Sunitinib—KCNH2—cerebellum—attention deficit hyperactivity disorder	0.000249	0.000437	CbGeAlD
Sunitinib—ABCG2—cerebellum—attention deficit hyperactivity disorder	0.000222	0.000389	CbGeAlD
Sunitinib—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000214	0.000376	CbGeAlD
Sunitinib—KCNH2—brain—attention deficit hyperactivity disorder	0.000202	0.000355	CbGeAlD
Sunitinib—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000181	0.000318	CbGeAlD
Sunitinib—ABCG2—brain—attention deficit hyperactivity disorder	0.00018	0.000316	CbGeAlD
Sunitinib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000164	0.000288	CbGeAlD
Sunitinib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000158	0.000277	CbGeAlD
Sunitinib—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000141	0.000248	CbGeAlD
Sunitinib—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000116	0.000204	CbGeAlD
Sunitinib—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000112	0.000196	CbGeAlD
Sunitinib—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000109	0.000192	CbGeAlD
Sunitinib—ABCB1—brain—attention deficit hyperactivity disorder	8.88e-05	0.000156	CbGeAlD
Sunitinib—RPS6KA2—Immune System—EP300—attention deficit hyperactivity disorder	3.97e-05	9.46e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.93e-05	9.38e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.9e-05	9.31e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.9e-05	9.31e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.9e-05	9.31e-05	CbGpPWpGaD
Sunitinib—YES1—Hemostasis—EP300—attention deficit hyperactivity disorder	3.89e-05	9.29e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.88e-05	9.26e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.87e-05	9.22e-05	CbGpPWpGaD
Sunitinib—CSNK1G2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.86e-05	9.21e-05	CbGpPWpGaD
Sunitinib—GRK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.86e-05	9.21e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.85e-05	9.19e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.82e-05	9.11e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.81e-05	9.08e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.74e-05	8.92e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.74e-05	8.91e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.73e-05	8.9e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.73e-05	8.89e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.7e-05	8.83e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.69e-05	8.81e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.69e-05	8.81e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.67e-05	8.75e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.67e-05	8.75e-05	CbGpPWpGaD
Sunitinib—AXL—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.66e-05	8.73e-05	CbGpPWpGaD
Sunitinib—TYK2—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.66e-05	8.72e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.65e-05	8.71e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.63e-05	8.65e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.63e-05	8.65e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.62e-05	8.64e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.62e-05	8.64e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—TPH2—attention deficit hyperactivity disorder	3.6e-05	8.58e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.6e-05	8.58e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.58e-05	8.53e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.57e-05	8.51e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	3.57e-05	8.51e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Immune System—EP300—attention deficit hyperactivity disorder	3.56e-05	8.5e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.56e-05	8.49e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.56e-05	8.49e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—DPYD—attention deficit hyperactivity disorder	3.54e-05	8.44e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.52e-05	8.39e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.52e-05	8.39e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.51e-05	8.38e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.51e-05	8.38e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	3.51e-05	8.37e-05	CbGpPWpGaD
Sunitinib—YES1—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.51e-05	8.36e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.5e-05	8.34e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Disease—EP300—attention deficit hyperactivity disorder	3.49e-05	8.32e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.49e-05	8.32e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.47e-05	8.28e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.46e-05	8.26e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.45e-05	8.24e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.45e-05	8.24e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.44e-05	8.21e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.43e-05	8.19e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.41e-05	8.14e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.41e-05	8.14e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.41e-05	8.13e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.37e-05	8.05e-05	CbGpPWpGaD
Sunitinib—FGFR1—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.36e-05	8.03e-05	CbGpPWpGaD
Sunitinib—STK11—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.35e-05	7.99e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.33e-05	7.95e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.33e-05	7.94e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.33e-05	7.93e-05	CbGpPWpGaD
Sunitinib—IRAK1—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.33e-05	7.93e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.29e-05	7.85e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.29e-05	7.85e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Metabolism—EP300—attention deficit hyperactivity disorder	3.28e-05	7.82e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.28e-05	7.82e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.28e-05	7.81e-05	CbGpPWpGaD
Sunitinib—TBK1—Immune System—EP300—attention deficit hyperactivity disorder	3.27e-05	7.81e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.27e-05	7.8e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.26e-05	7.78e-05	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.24e-05	7.73e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.24e-05	7.72e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.24e-05	7.72e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.23e-05	7.7e-05	CbGpPWpGaD
Sunitinib—TYK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.23e-05	7.7e-05	CbGpPWpGaD
Sunitinib—INSR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.22e-05	7.69e-05	CbGpPWpGaD
Sunitinib—CAMK2G—Immune System—EP300—attention deficit hyperactivity disorder	3.21e-05	7.66e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.21e-05	7.65e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.19e-05	7.61e-05	CbGpPWpGaD
Sunitinib—FGFR2—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.19e-05	7.6e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.18e-05	7.58e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.18e-05	7.58e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.17e-05	7.57e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.17e-05	7.56e-05	CbGpPWpGaD
Sunitinib—ABCC4—Hemostasis—EP300—attention deficit hyperactivity disorder	3.14e-05	7.5e-05	CbGpPWpGaD
Sunitinib—MAP3K3—Immune System—EP300—attention deficit hyperactivity disorder	3.14e-05	7.49e-05	CbGpPWpGaD
Sunitinib—KIT—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.13e-05	7.47e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.13e-05	7.47e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.1e-05	7.39e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.09e-05	7.38e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.08e-05	7.35e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.07e-05	7.32e-05	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.06e-05	7.31e-05	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.06e-05	7.31e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.06e-05	7.29e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.05e-05	7.27e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.04e-05	7.24e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.02e-05	7.2e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.02e-05	7.19e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.01e-05	7.17e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3e-05	7.15e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.98e-05	7.11e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.98e-05	7.11e-05	CbGpPWpGaD
Sunitinib—FGFR1—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.97e-05	7.09e-05	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.97e-05	7.09e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.97e-05	7.07e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.96e-05	7.07e-05	CbGpPWpGaD
Sunitinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	2.96e-05	7.06e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.95e-05	7.02e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.95e-05	7.02e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.95e-05	7.02e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.94e-05	7.02e-05	CbGpPWpGaD
Sunitinib—IRAK4—Immune System—EP300—attention deficit hyperactivity disorder	2.92e-05	6.96e-05	CbGpPWpGaD
Sunitinib—FYN—Developmental Biology—EP300—attention deficit hyperactivity disorder	2.91e-05	6.95e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.91e-05	6.94e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Developmental Biology—EP300—attention deficit hyperactivity disorder	2.9e-05	6.91e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.89e-05	6.89e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.88e-05	6.86e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.87e-05	6.85e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.87e-05	6.85e-05	CbGpPWpGaD
Sunitinib—FYN—Hemostasis—EP300—attention deficit hyperactivity disorder	2.86e-05	6.82e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.85e-05	6.8e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.84e-05	6.77e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Immune System—EP300—attention deficit hyperactivity disorder	2.84e-05	6.77e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.83e-05	6.76e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.82e-05	6.74e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Disease—EP300—attention deficit hyperactivity disorder	2.82e-05	6.72e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.82e-05	6.72e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.8e-05	6.69e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.79e-05	6.65e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.78e-05	6.62e-05	CbGpPWpGaD
Sunitinib—JAK2—Developmental Biology—EP300—attention deficit hyperactivity disorder	2.77e-05	6.61e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.75e-05	6.55e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.74e-05	6.54e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.74e-05	6.53e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.74e-05	6.53e-05	CbGpPWpGaD
Sunitinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	2.72e-05	6.48e-05	CbGpPWpGaD
Sunitinib—JAK2—Hemostasis—EP300—attention deficit hyperactivity disorder	2.72e-05	6.48e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.71e-05	6.47e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.71e-05	6.46e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.7e-05	6.44e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.67e-05	6.37e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.67e-05	6.36e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.61e-05	6.23e-05	CbGpPWpGaD
Sunitinib—PTK2B—Immune System—EP300—attention deficit hyperactivity disorder	2.6e-05	6.2e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.6e-05	6.2e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.59e-05	6.18e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	2.58e-05	6.15e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.58e-05	6.15e-05	CbGpPWpGaD
Sunitinib—FYN—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.57e-05	6.14e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.56e-05	6.12e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.56e-05	6.11e-05	CbGpPWpGaD
Sunitinib—BLK—Immune System—EP300—attention deficit hyperactivity disorder	2.54e-05	6.05e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	2.54e-05	6.05e-05	CbGpPWpGaD
Sunitinib—FGR—Immune System—EP300—attention deficit hyperactivity disorder	2.53e-05	6.03e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.49e-05	5.94e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.48e-05	5.92e-05	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.45e-05	5.84e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.44e-05	5.83e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.36e-05	5.64e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.36e-05	5.62e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.3e-05	5.49e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.29e-05	5.47e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.29e-05	5.45e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.27e-05	5.4e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.23e-05	5.31e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.23e-05	5.31e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—COMT—attention deficit hyperactivity disorder	2.18e-05	5.2e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—MAOA—attention deficit hyperactivity disorder	2.16e-05	5.16e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	2.16e-05	5.15e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	2.15e-05	5.12e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.11e-05	5.04e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.11e-05	5.02e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.06e-05	4.92e-05	CbGpPWpGaD
Sunitinib—YES1—Immune System—EP300—attention deficit hyperactivity disorder	2.04e-05	4.87e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.97e-05	4.71e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.96e-05	4.68e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.95e-05	4.64e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.95e-05	4.64e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.95e-05	4.64e-05	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—EP300—attention deficit hyperactivity disorder	1.94e-05	4.62e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.91e-05	4.56e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.9e-05	4.53e-05	CbGpPWpGaD
Sunitinib—TYK2—Immune System—EP300—attention deficit hyperactivity disorder	1.88e-05	4.48e-05	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—EP300—attention deficit hyperactivity disorder	1.86e-05	4.43e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.85e-05	4.42e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.84e-05	4.38e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.83e-05	4.36e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—EP300—attention deficit hyperactivity disorder	1.82e-05	4.35e-05	CbGpPWpGaD
Sunitinib—KIT—Immune System—EP300—attention deficit hyperactivity disorder	1.82e-05	4.35e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.82e-05	4.34e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.78e-05	4.24e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.74e-05	4.15e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.74e-05	4.14e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—EP300—attention deficit hyperactivity disorder	1.74e-05	4.14e-05	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—EP300—attention deficit hyperactivity disorder	1.73e-05	4.13e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—EP300—attention deficit hyperactivity disorder	1.73e-05	4.12e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—EP300—attention deficit hyperactivity disorder	1.71e-05	4.09e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—EP300—attention deficit hyperactivity disorder	1.68e-05	4.02e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.68e-05	4.01e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.62e-05	3.86e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.61e-05	3.84e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—EP300—attention deficit hyperactivity disorder	1.6e-05	3.81e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—EP300—attention deficit hyperactivity disorder	1.59e-05	3.8e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—EP300—attention deficit hyperactivity disorder	1.59e-05	3.8e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	1.56e-05	3.73e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.56e-05	3.72e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.56e-05	3.72e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—EP300—attention deficit hyperactivity disorder	1.56e-05	3.71e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.56e-05	3.71e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	1.55e-05	3.7e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.52e-05	3.63e-05	CbGpPWpGaD
Sunitinib—FYN—Immune System—EP300—attention deficit hyperactivity disorder	1.5e-05	3.58e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—EP300—attention deficit hyperactivity disorder	1.49e-05	3.56e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.48e-05	3.53e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—EP300—attention deficit hyperactivity disorder	1.47e-05	3.51e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—EP300—attention deficit hyperactivity disorder	1.44e-05	3.42e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—EP300—attention deficit hyperactivity disorder	1.43e-05	3.4e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—EP300—attention deficit hyperactivity disorder	1.38e-05	3.3e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—EP300—attention deficit hyperactivity disorder	1.38e-05	3.28e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.32e-05	3.15e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—EP300—attention deficit hyperactivity disorder	1.32e-05	3.14e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.25e-05	2.99e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.22e-05	2.9e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.2e-05	2.86e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.2e-05	2.86e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	1.2e-05	2.86e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	1.18e-05	2.81e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.18e-05	2.81e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.18e-05	2.81e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	1.18e-05	2.81e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.17e-05	2.79e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.12e-05	2.67e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.12e-05	2.66e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.1e-05	2.61e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.03e-05	2.46e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.01e-05	2.4e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.69e-06	2.31e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.64e-06	2.3e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.58e-06	2.29e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—EP300—attention deficit hyperactivity disorder	9.35e-06	2.23e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	9.27e-06	2.21e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.21e-06	2.2e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.12e-06	2.18e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	7.26e-06	1.73e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	7.21e-06	1.72e-05	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	6.7e-06	1.6e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	5.05e-06	1.21e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.11e-06	7.43e-06	CbGpPWpGaD
